Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) was the target of a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 1,960,000 shares, a decrease of 10.9% from the September 30th total of 2,200,000 shares. Approximately 5.7% of the shares of the company are short sold. Based on an average daily trading volume, of 318,400 shares, the short-interest ratio is presently 6.2 days.
Cellectar Biosciences Stock Performance
Cellectar Biosciences stock remained flat at $2.05 during mid-day trading on Wednesday. 198,262 shares of the company’s stock were exchanged, compared to its average volume of 918,773. Cellectar Biosciences has a 12-month low of $1.82 and a 12-month high of $4.45. The stock’s 50 day simple moving average is $2.10 and its 200 day simple moving average is $2.53. The stock has a market cap of $73.49 million, a price-to-earnings ratio of -0.67 and a beta of 0.99.
Institutional Trading of Cellectar Biosciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC acquired a new stake in Cellectar Biosciences during the third quarter valued at approximately $51,000. XTX Topco Ltd boosted its stake in Cellectar Biosciences by 432.4% in the 2nd quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 51,413 shares in the last quarter. Vanguard Group Inc. boosted its stake in Cellectar Biosciences by 146.7% in the 1st quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock valued at $4,741,000 after buying an additional 708,191 shares in the last quarter. Rosalind Advisors Inc. boosted its stake in Cellectar Biosciences by 335.4% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,705,616 shares of the biopharmaceutical company’s stock valued at $6,764,000 after buying an additional 2,084,138 shares in the last quarter. Finally, AIGH Capital Management LLC boosted its stake in Cellectar Biosciences by 8.2% in the 2nd quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock valued at $7,590,000 after buying an additional 231,270 shares in the last quarter. Institutional investors own 16.41% of the company’s stock.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on Cellectar Biosciences
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Featured Stories
- Five stocks we like better than Cellectar Biosciences
- The 3 Best Retail Stocks to Shop for in August
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How to Use the MarketBeat Dividend Calculator
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.